Stiripentol

• CAT Number: R003209
• CAS Number: 49763-96-4
• Molecular Formula: C14H18O3
• Molecular Weight: 234.30
• Purity: 98%
• Synonyms: 1-(1,3-Benzodioxol-5yl)-4,4-dimethyl-1-penten-3-ol; 4,4-Dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol; BCX 2600
• Target: GABRG3
• Target Protein: Q99928
• Solubility: >9.9mg/mL in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 1.58 μM (CYP3A4), 3.29 μM (CYP2C19)
• IUPAC Name: (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
• InChI: InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+
• InChIKey: IBLNKMRFIPWSOY-FNORWQNLSA-N
• SMILES: CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O

Stiripentol（Cat No.:R003209）is an anticonvulsant medication used as an adjunctive treatment for Dravet syndrome, a severe form of epilepsy. It enhances the effect of gamma-aminobutyric acid (GABA) by modulating GABA receptors and inhibiting certain enzymes responsible for drug metabolism, particularly of clobazam. This dual action helps to reduce the frequency and severity of seizures in patients who are resistant to other treatments. Stiripentol’s ability to improve seizure control in combination with other antiepileptic drugs makes it a valuable option for managing refractory epilepsy, offering enhanced quality of life for patients.